<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab2">
 <label>Table 10.2</label>
 <caption>
  <p>List of drugs that have antiviral activity compounds against SARS-CoV-2</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Antiviral agents</th>
    <th>Drug targets</th>
    <th>Reported mechanism of action</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td colspan="3">
     <italic>Virus-based treatment approaches</italic>
    </td>
   </tr>
   <tr>
    <td>Favipiravir</td>
    <td>RdRp</td>
    <td>Inhibits RdRp</td>
   </tr>
   <tr>
    <td>Ribavirin</td>
    <td>RdRp</td>
    <td>Inhibits viral RNA synthesis and mRNA capping</td>
   </tr>
   <tr>
    <td>Penciclovir</td>
    <td>RdRp</td>
    <td>Inhibits RdRp</td>
   </tr>
   <tr>
    <td>Remdesivir (GS-5734)</td>
    <td>RdRp</td>
    <td>Terminates the non-obligate chain</td>
   </tr>
   <tr>
    <td>Lopinavir</td>
    <td>3CLpro</td>
    <td>Inhibits 3CLpro</td>
   </tr>
   <tr>
    <td>Ritonavir</td>
    <td>3CLpro</td>
    <td>Inhibits 3CLpro</td>
   </tr>
   <tr>
    <td>Darunavir and cobicistat</td>
    <td>3CLpro</td>
    <td>Inhibits 3CLpro</td>
   </tr>
   <tr>
    <td>ASC09F (HIV protease inhibitor)</td>
    <td>3CLpro</td>
    <td>Inhibits 3CLpro</td>
   </tr>
   <tr>
    <td>Nafamostat</td>
    <td>Spike glycoprotein</td>
    <td>Inhibits spike-mediated membrane fusion</td>
   </tr>
   <tr>
    <td>Griffithsin</td>
    <td>Spike glycoprotein</td>
    <td>Inhibits spike-mediated membrane fusion</td>
   </tr>
   <tr>
    <td>Arbidol (umifenovir)</td>
    <td>–</td>
    <td>–</td>
   </tr>
   <tr>
    <td>Oseltamivir</td>
    <td>–</td>
    <td>–</td>
   </tr>
   <tr>
    <td colspan="3">
     <italic>Host-based treatment approaches</italic>
    </td>
   </tr>
   <tr>
    <td>Recombinant interferons</td>
    <td>Interferon response</td>
    <td>Exogenous interferons</td>
   </tr>
   <tr>
    <td>Chloroquine</td>
    <td>Endosomal acidification</td>
    <td>A lysosomotropic base that appears to disrupt intracellular trafficking and viral fusion events</td>
   </tr>
   <tr>
    <td>Nitazoxanide</td>
    <td>Interferon response</td>
    <td>Induces the host innate immune response to produce interferons by the host’s fibroblasts and protein kinase R (PKR) activation</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
